



BIOCENTURY Grand Rounds

IN COLLABORATION WITH INSIGHTS PARTNER MCKINSEY & COMPANY

SEPT
9-11
2024

NASHVILLE, TENNESSEE
Four Seasons Hotel Nashville

ADVANCED REGISTRATION IS NOW OPEN
EXPIRES AUGUST 2ND

BIOCENTURYGRANDROUNDS.COM

Organized by

BIOCENTURY

Insights Partner

McKinsey
& Company

Founding Investors



Join BioCentury's Signature R&D Conference

BioCentury Grand Rounds is a new interdisciplinary forum of top academic and biopharma R&D leaders to showcase groundbreaking research, clinical insights, and transformative technologies with significant commercial potential.



At BioCentury Grand Rounds, discover the next wave of biotech breakthroughs and the people driving them. Be part of the dialogue solving today's problems in translation to enable tomorrow's medicines.

Who you will meet:

Academic
Translational
Researchers

Biopharma
R&D Leaders

Thought
Leaders: From
Today and
Tomorrow

Early Stage
Investors

Founders,
CEOs

The conference will:

- Introduce VCs and pharmas to emerging academic innovators and physician scientists — from all regions — working on early-stage science with commercial potential
- Gather innovators and entrepreneurs to present leading edge discoveries, via presentations and poster sessions
- Engage thought leaders to discuss critical challenges at the interface of academia and industry

What to Expect



Debate R&D Strategy

Discuss critical bottlenecks in translation of breakthrough science to successful drug development programs



Discover Groundbreaking Research

40+ Presenting Companies and 50+ Translational Posters — selected by BioCentury



Schedule Meetings

Partner with investors, biopharma leaders, emerging academic innovators



Network with Peers

Build connections with decision-makers in an intimate setting



Take Home the Conference Report

Insights Partner McKinsey & Company looks at challenges that must be solved to translate breakthrough innovations

Why Attend?

A unique convergence of minds

Grand Rounds is not just another industry conference; it's a vital intersection of academia, industry, and investment within the biopharma sphere. This event is specifically designed to foster collaboration and networking among academic innovators, R&D leaders, venture capitalists, and biotech executives, facilitating discussions at the crucial academia/industry interface to drive innovation.

Focus on forward-thinking innovation

The conference is deeply invested in unveiling the future of biopharma, spotlighting emerging science and technology that promises to revolutionize patient care. It stands out by dedicating itself to the exploration of mechanistic biology and the translation of high-potential academic discoveries into tangible drug development opportunities, highlighting new best practices from AI to pharmacology.

Strategic industry dialogues and deep dives

Beyond general networking, Grand Rounds offers a platform for critical industry dialogues that address and aim to overcome the bottlenecks in translating academic discoveries to commercial successes. Discussions are not just theoretical but are geared towards actionable solutions that can accelerate drug development.

Catalyst for groundbreaking collaborations

Grand Rounds is the catalyst for future biotech innovation, bridging gaps between early-stage research and its commercialization. It's an event where the next big breakthroughs in biotech R&D are not just discussed but actively shaped through collaborations that span continents and disciplines, offering unparalleled access to a curated, high-caliber network of industry changemakers.

An experience beyond the conference room

Set in Nashville, the conference promises not just insightful panels and sessions but an immersive networking experience that leverages the city's rich cultural and innovative ecosystem. This "destination experience" is crafted to strengthen professional relationships in a vibrant, memorable setting.

Steering Committee



Amy Abernethy, M.D., Ph.D.
Former Principal Deputy
Commissioner
FDA



Chris Arendt, Ph.D.
CSO, Head of Research
Takeda



Jamil Beg
Partner
SV Health Investors



Luciana Borio, M.D.
Venture Partner
Arch Venture Partners



Shelley Chu, M.D., Ph.D.
Partner, Head of Biotech
Lightspeed Ventures



Mark Currie, Ph.D.
Venture Partner
Iaso Ventures



Simone Fishburn, Ph.D.
VP & Editor in Chief
BioCentury Inc.



Todd Foley
Managing Director
MPM BioImpact




Kathleen Giacomini, Ph.D.
Dean, School of Pharmacy
UCSF



David Goldstein, Ph.D.
Co-founder & CEO
Actio Biosciences




Jane Grogan, Ph.D.
EVP, Head of Research
Biogen



Najat Khan, Ph.D.
Chief Data Science Officer
Recursion




Sophie Kornowski, Pharm.D.
CEO
Boston Pharmaceuticals



Olivier Leclerc
Senior Partner
McKinsey & Company



John Lepore, M.D.
CEO
ProFound Therapeutics




Mathai Mammen, M.D., Ph.D.
Chairman & CEO
FogPharma



Fiona Marshall, Ph.D.
President of Biomedical
Research
Novartis



Antoine Papiernik
Chairman & Managing
Partner
Sofinnova Partners




Kush Parmar, M.D., Ph.D.
Managing Partner
SAM Ventures



Cary Pfeffer, M.D.
Partner
Third Rock Ventures



Robert Plenge, M.D., Ph.D.
EVP, Chief Research Officer
Bristol Myers Squibb



Daniel Reich, M.D., Ph.D.
Chief, Translational
Neuroradiology Section,
NINDS, NIH Attending
Neuroradiologist, NIH Clinical
Center



Klaus Romero, M.D.
CEO
Critical Path Institute



David Satjin, Ph.D.
SVP, Head of Discovery
Genmab



Paul Peter Tak, M.D., Ph.D.
President & CEO
Candel Therapeutics



Nikhil Wagle, M.D.
VP & Global Head of
Translational Medicine
Genentech



Douglas Williams, Ph.D.
Head of R&D
Sana Biotechnology


Showcase your translational science to top-tier investors & biopharma executives

At Grand Rounds, get in the room with the right people to speed the path from your discoveries to value-creating medicines.



INNOVATIVE DRUG THERAPIES

- CAR Ts, TCR T cells, and other cell therapies
- Gene therapies and gene editors
- mAbs, ADCs, bispecifics or radioligand therapies
- RNAi, antisense or other nucleic acid drug candidates



TARGETS AND BIOMARKERS

- New disease targets with evidence from human biology
- Advanced techniques in target discovery
- Novel chemistries for hard-to-drug targets
- Biomarkers enabling precision medicine



ADVANCED TECHNIQUES

- Platforms and methodologies for drug design
- New cell - or animal-based disease models
- Cutting-edge delivery technologies
- Predictive models for tox, ADME or other drug-like properties



AND MORE

AUG
1
2024

DEADLINE: Submit your poster title and abstract by Aug. 1, 2024

TOP POSTER SPOTLIGHT: The top academic poster will be awarded a lighting round presentation in front of the conference's full audience of biotech decision-makers.

Get started at biocentury.com/academic-poster



Initial Presenting Company Class



CALL FOR PRESENTERS

Join us in shaping the future of healthcare innovation and connect with a community dedicated to advancing preclinical and early-stage development.

BioCentury is curating a lineup of emerging biotechs with cutting-edge innovations and groundbreaking advancements to join this year's Presenting Company Class of 2024.



- Share your story to potential partners and investors at Grand Rounds
- Access the partnering platform to schedule 1x1 meetings with delegates
- Upload a digital presentation on the partnering platform to drive more meeting requests



WE ARE ACCEPTING NOMINATIONS FOR A LIMITED NUMBER OF OPEN SLOTS FOR COMPANIES THAT:

- Pre-seed, seed, or series A
- Early in development
- Rooted in or connected with academia
- Eager to share their vision, progress, and future plans



For any questions or additional information, please contact:
TIM TULLOCH, Director, Corporate Alliances & Business Development
conferences@biocentury.com



Preliminary Agenda

Monday, September 9, 2024

- 11:00 am – 3:00 pm **Pre-Event Networking Excursion & Lunch**
Join us for a visit to the National Museum of African American Music, including a delightful lunch. Get the networking started early while immersing yourself in one of the jewels of Nashville, the only museum dedicated to the history of Black music, integrating history and interactive technology to bring musical heroes of the past to the present. Discover the stories behind the rhythms and melodies that have shaped genres from jazz and blues to hip-hop and R&B.
**Limited Capacity, additional registration required. Email: conferences@biocentury.com for more information.*
- 4:00 pm – 4:30 pm General Registration & Networking
- 4:30 pm – 5:30 pm **Opening Plenary & Fireside Chat: Heads of Pharma Research, in Conversation**
Chair: Simone Fishburn, VP & Editor in Chief, BioCentury
Panelists: Jane Grogan, Ph.D., EVP, Head of Research, Biogen
Fiona Marshall, Ph.D., President of Biomedical Research, Novartis
- 5:30 pm – 7:00 pm Networking Welcome Reception

Tuesday, September 10, 2024

- 7:30 am – 8:45 am **General Registration & Networking Breakfast**
- 8:00 am – 8:45 am **Breakfast Workshop: Getting Corporate Formation Right**
Getting the science to work is arguably not the hardest part of being a scientific founder. Creating a company can be even more of a challenge, from protecting IP to raising money. What do scientific founders and executives need to understand prior to forming a life science company? How do you build a company from Day 1 that is attractive to future partners and investors? What are common pitfalls that trip up first-time CEOs?
This interactive workshop brings together academics, lawyers, investors, and dealmakers to discuss how to get company formation right.
Panelists: Chris Garabedian, Venture Portfolio Manager, Perceptive Advisors and CEO, Xontogeny
Guru Laxmikanthan, Ph.D., Patent Attorney, Nutter
Jim Ray, Ph.D., Executive Director, Neurodegenerative Consortium, MD Anderson
- 8:00 am – 5:30 pm C-level Partnering Meetings
- 8:45 am – 9:00 am Official Welcome from BioCentury
- 9:00 am – 5:30 pm Presenting Companies

9:00 am – 10:00 am

Conference Report: Reimagining translation: how to unlock the next wave of breakthrough treatments

Biotechnology breakthroughs rely on efficient and effective mechanisms to advance high-potential translational research. At a moment of accelerated biopharma innovation, there is an opportunity for industry, academia and other stakeholders to collaborate in new ways to help unlock the next wave of breakthrough therapies. Insights Partner McKinsey & Company examines the current state of biopharma research and forecasts where translation is headed in the 2024 Grand Rounds Conference Report. Advanced access to McKinsey's report will be available exclusively to all Grand Rounds delegates.

Co-chairs: Peter Wright, Ph.D., Partner, McKinsey & Company
Guang Yang, Ph.D., Partner, McKinsey & Company

GRAND ROUNDS I: TRANSLATIONAL BOTTLENECKS

Uncorking innovation: Critical issues hampering the acceleration of translation

Against the backdrop of escalating discoveries and breakthroughs over the past decade, critical bottlenecks are holding back their conversion to value-driving drug development. Inefficiencies in translation extend from poor disease models to underdeveloped delivery technology to mismatched expectations for what constitutes validation. The Bottleneck Rounds will unpack the strategies for overcoming these roadblocks.

10:00 am – 10:40 am

From causal biology to preclinical validation: What makes the grade in 2024?

Scientist-entrepreneurs hope to win attention and money from investors and pharmas, but often run afoul of what evidence constitutes preclinical validation. Drug developers are making clear that causal biology is the North Star, however reaching it is not straightforward. The issue spans the target's origin, model systems, experimental design, statistical robustness and effect size that will convince the buy-side a signal is a meaningful result. This Round will discuss what investors and pharmas want to see, and how ambitious scientists can strengthen the case for translating their research projects from academia to industry.

Chair: John Lepore, M.D., CEO, ProFound Therapeutics

Panelist: Chris Hollowood, Ph.D., CEO Syncona

Carrie Jones, Ph.D., Associate Professor of Pharmacology, Vanderbilt University

Chaitan Khoshla, Ph.D., Professor of Chemistry, Stanford University

Nikhil Wagle, M.D., VP & Global Head of Translational Medicine

10:40 am – 11:10 am

Morning Networking Break

11:10 am – 11:50 am

The human first era is here: Is there still value in new animal models?

Animal models arguably have done what they can for translation. They'll likely persist for PK and tox studies. For functional readouts in disease, however, use of animal models is driven by inertia, routine, regulatory requirements and lack of other options, rather than their predictive potential. With investors and pharmas increasingly seeing human data as ground zero for drug development, where should researchers be focused on building model systems? This Round will discuss what animal models are proving their worth, where transformational new ones might emerge, and what alternative systems, such as patient-derived iPSCs and organoids, are yielding proof of concept that investors, pharmas and regulators will accept.

Chair: Anika Gupta, Ph.D., Principal, GV

Panelists: Manuel Ascano, Ph.D., Associate Professor of Biochemistry, Vanderbilt University School of Medicine




11:50 am – 12:30 pm

Delivery on demand: Still the elephant in the room

The rush of new modalities has not been matched by advances in highly targeted delivery, particularly for nucleic acid therapies. Enabling DNA- and RNA-based therapies to reach any cell in the body, on demand, would open untold target space and therapeutic opportunities. Beyond viral vectors, a slow wave in nonviral technologies is building. This Round will evaluate which approaches to tissue-specific delivery promise greater success and consider whether precompetitive approaches or delivery-focused service models will benefit both academic researchers and drug developers.

Chair: Douglas Williams, Ph.D., Head of R&D, Sana Biotechnology

Panelist: Melissa Bonner, Ph.D., Chief Scientific Officer, Nvelop Therapeutics
Kevin Friedman, Ph.D., Co-founder & CEO, Kelonia Therapeutics
Carolyn Zimmermann, Chief Business Officer, SonoThera



12:30 pm – 1:30 pm

Networking Lunch

GRAND ROUNDS II: THE MODALITY GROUNDBREAKERS

A mountain of modalities: Now comes the translational loop

Academic innovators have powered most of the groundbreaking technologies that have yielded mountains of new modalities from CRISPR to gene therapies to CAR T to mRNA. The handoff to industry is allowing such discoveries to reach patients, but some of these transformations must overcome limitations that cap their use. For these, the translational loop puts the creation of next-generation iterations back in the hands of researchers. The Modality Groundbreaker Rounds will identify these potential solutions, and address how drug developers can prioritize among the innovations in a modality to bring treatments to patients most efficiently.



1:30 pm – 2:10 pm

The heyday of AAV engineering is here: Will it deliver?

AAVs have all but crowded out other viruses as the gene therapy vector of choice, and now promise to go beyond genetic diseases via the creation of vectorized antibodies and proteins that could compete with traditional biologics. Engineering advances with capsid optimization, inducible expression technologies and packaging are solving for toxicities, limits on targeting precision, cargo size, scalability and other manufacturing hurdles. This Round will evaluate the most efficient ways for drug developers to exploit this burst of innovation and consider whether other vectors — viral or non-viral — will see the same kind of progress and diversify the options.

Panelists: Zandy Forbes, Ph.D., President & CEO MeiraGTx
Nicole Paulk, Ph.D., Founder & CEO, Siren Biotechnology
Lexi Rovner, Ph.D., Co-founder & CEO, 64x Bio



2:10 PM – 2:50 PM

The regenerative moment: Are iPSCs poised to reshape the cell therapy toolbox?

With more than 20 types of cell therapies derived from iPSCs in their pipelines, biotechs are on the cusp of breaking open a major new avenue for engineering cell products with a desired set of functions. This Round will ponder important questions that still remain: In the age of single-cell transcriptomics, what can be gleaned about the fidelity of reprogramming and cell durability? What is the field learning about best practices for manipulating and scaling the cells without compromising their benefits? And what bar must they beat vis a vis regenerative approaches based on protein therapeutics or traditional modalities?



Panelists: Erin Kimbrel, Ph.D., President & Head of Astellas Institute for Regenerative Medicine, Astellas
Samuel Lynch, Chairman & CEO, Lynch Regenerative Medicine, and Board Director, Vanderbilt University Medical Center
Marinna Madrid, Ph.D., Co-founder & Chief Product Officer, Cellino
Stephanie Oestreich, Ph.D., Managing Director, Myeloma Investment Fund
Krishnendu Roy, Ph.D., Professor of Engineering, Vanderbilt University

2:50 pm – 3:20 pm

Afternoon Networking Break

3:20 pm – 4:00 pm

Maximizing the impact of gene editing: Incremental improvements, or leaps to newer technologies?

CRISPR-Cas9 has catalyzed a world of therapeutic programs, but the fundamental limitations of gene editing still haven't been solved. Researchers have discovered new nucleases yielding base, prime and epigenetic editors that allow pinpoint changes and avoid double-stranded DNA breaks. Next-generation transposases and recombinases that facilitate large-scale genomic alterations are coming up fast. The potential for off-target edits remains, however. This Round will ask whether incremental advances in clinical-stage technologies can remove that barrier, or whether it will take a shift to newer types of biological machinery.



Chair: Deborah Palestrant, Ph.D., Partner, 5AM Ventures, Exec. Chair, 4:59 Initiative

Panelist: Clare Murray, Ph.D., SVP Corporate Development & Operations, Life Edit Therapeutics
Gregory Newby, Ph.D., Assistant Professor, Johns Hopkins University

4:00 pm – 4:40 pm

Souping up cancer cell therapies: Is the juice worth the squeeze?

As cytotoxic cell therapies have carved out their niche, cancer researchers are churning out new strategies to improve their performance, from knocking out genes that promote exhaustion, to adding in stimulators or switches that respectively boost or limit their expansion capacity. What are the limits to the number and types of manipulations these cells can undergo? This Round will identify which CAR T cell manipulation strategies are rising above the noise, particularly for solid tumors, and ask whether other cancer-killing cell types such as TILs and NK cells can benefit as well.



Chair: Kristin Hege, M.D., Board Member, Adaptimmune, Mersana, Kelonia and former SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb

Panelists: Mark Frolich, M.D., CEO, Indapta Therapeutics
Sasha Huhlov, Ph.D., Head of Search and Evaluation, Center for External Innovation, Takeda
Carl Novina, M.D., Ph.D., Professor, Dana Farber Cancer Institute

4:40 pm – 5:30 pm

Closing the innovation gap: Partnerships for next-gen treatments

In the age of big data, causal human biology and modality expansion there is an opportunity to significantly accelerate and broaden the scope of clinical translation through innovation partnerships. In this panel, biopharma execs, VCs, and academic leaders discuss how to join forces to find the next generation of breakthrough treatments early and bring them to market within years, not decades.

Chair: Daniel von Bornstädt, M.D., Associate Partner, McKinsey & Company
Panelists: Stephen Fesik, Ph.D., Orrin H. Ingram II Chair Cancer Research & Professor of Biochemistry, Pharmacology, and Chemistry, Vanderbilt University
Sophie Kornowski, PharmD, CEO, Boston Pharmaceuticals

5:30 pm – 7:00 pm Networking Reception

6:00 pm – 7:00 pm **Poster Spotlight Presentations: At the Forefront of Translational Innovation**

7:30 pm – 10:00 pm **Rounds About Town**

Build stronger connections with academics, investors, and biopharma execs by joining BioCentury's "Rounds About Town" walking tour. Visit Nashville honky-tonks, live music venues, and other cultural sites in Music City as you network with Grand Rounds attendees.

**Depart from Four Seasons lobby. Please note food, drinks, and other expenses must be paid for separately.*

[Click here for more information](#)

Wednesday, September 11, 2024

8:00 am – 9:00 am **General Registration & Networking Breakfast**

8:00 am – 3:30 pm C-level Partnering Meetings

9:00 am – 12:30 pm Presenting Companies

9:00 am – 10:00 am **Keynote Address: Blowing up the small molecule paradigm**

Chair: Gregory Verdine, Ph.D., Co-Founder, President & CEO, LifeMine Therapeutics, and Professor of Chemistry, Harvard University



GRAND ROUNDS III: THE HUMAN DATA REVOLUTION

The human data revolution: Leveraging academic-industry symbiosis

Academics have largely been the keepers of both the data and the methodological innovations that will advance the data revolution in biomedical science. Industry is critically dependent on applying the best tools to harness these data lakes to uncover causal disease-driving targets, predictive correlates of response and granular understanding of disease subtypes. This marriage of academic science with industry's needs could change the probability of success in discovery R&D by orders of magnitude. But the path is not simple. The Human Data Revolution Rounds will identify what must take place to make these data troves fit for purpose.

10:00 am – 10:40 am

Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity



Data lakes are only as useful as the analytical methods that sift through them. The challenge is to mine targets and biomarkers from trillions of data points from omics biobanks and massively parallel functional screens. Long-established analytical methods now sit alongside an explosion in new techniques, including large language models. This Round will discuss which analytical methods are gaining consensus as the right tools for extracting actionable insights and look ahead to the bleeding edge methods that will define the next era.

Chair: Karen Tkach Tuzman, Ph.D., Director of Biopharma Intelligence and Head of Discovery and Preclinical Research, BioCentury

Panelists: Daniel Burkhardt, Ph.D., Manager of Strategic Scientific Projects, Cellarity
Colin Hill, Co-founder & CEO, Aitia
Najat Khan, Ph.D., Chief R&D Officer and CCO,
Recursion
Wei-Qi Wei, M.D., Ph.D., Associate Professor, Department of Biomedical Informatics, Vanderbilt University Medical Center

10:40 am – 11:10 am

Morning Networking Break

11:10 am – 11:50 am



Data-for-purpose: Go big, go deep, or go long?

In an ideal world, researchers would have access to longitudinal high-resolution data on large and diverse human populations. In real life, logistical constraints usually force trade-offs. When is it best to prioritize population size, and when is the depth of data resolution per person more valuable? What questions are only solvable with longitudinal measurements? And will anonymized tokenization and data linkage make collection of these high-value datasets more routine? This Round will discuss what leading drug developers, academics and investors view as the optimal paths to making data fit for purpose.

Chair: Amy Abernethy, Ph.D., M.D., Co-founder, Highlander Health

Panelists: Gonçalo Abecasis, Ph.D., VP & Chief Genomics and Data Science Officer, Regeneron

Caroline Chung, M.D., VP, Chief Data Officer & Assoc Prof Radiation Oncology & Radiology, MD Anderson Cancer Center

David Goldstein, Ph.D., Co-founder & CEO, Actio Biosciences

Mathai Mammen, M.D., Ph.D., Chairman & CEO, FogPharma

Elizabeth Ann Stringer, Ph.D., Chief Scientific Officer, Nashville Biosciences

GRAND ROUNDS IV: THE DISEASE BIOLOGY BOOM



While you were away: Strides in disease biology presage a translational boom

Industry's focus on specific diseases has waxed and waned, driven by the commercial landscape. All the while, academic labs have been uncovering new disease biology and sowing the ground for leaps forward in translation. As obesity, inflammation and immunity, and neuroscience come back into favor for pharmas and investors, research labs are offering new targets, mechanisms of action, modalities and strategic approaches to propel those fields into a new age. The Disease Biology Rounds will elucidate how emerging science may make drug developers better prepared to serve these large, chronic diseases than the last time around.

11:50 am – 12:30 pm



Unlocking progress in neurology: How to build the case for a new target

The call to researchers is clear: Deliver new targets and biomarkers that enable industry to reinvent how neurodegenerative and neuropsychiatric diseases are treated. Multi-omics can yield new genetic risk factors and insight into disease mechanisms that can point to new targets, but dismal preclinical models are a roadblock. This Round will explore what it will take to build a strong case for a new target in the era of human data, including where EEG-defined signatures, imaging tools such as MRI, and clinical and digital phenotyping fit into the picture.

Chair: Selina Koch, Ph.D., Executive Editor, Head of Intelligence & Research, BioCentury

Panelists: Jamil Beg, Partner, SV Health Investors
Nancy Cox, Ph.D., Professor of Medicine, Vanderbilt University Medical Center
Daniel Reich, M.D., Ph.D., Chief, Translational Neuroradiology Section, NINDS,
NIH Attending Neuroradiologist, NIH Clinical Center
Jill Richardson, Ph.D., Head U.K. Neuroscience, Executive Director MRL, Merck/
MSD
Adam Savitz, MD, Ph.D., Chief Medical Officer, Alto Neuroscience

12:30 pm – 1:30 pm

Lunchtime Plenary

Chair: Luciana Borio, M.D., Venture Partner, Arch Ventures, ex-FDA

Panelist: Robert Carnahan, Ph.D, Professor of Pediatrics,
Assoc. Dir. Vanderbilt Vaccine Center,
Vanderbilt University Medical Center

1:30 pm – 2:10 pm

Immunity and inflammation inflection point: What determines the direction from here?

Dramatic improvements in treating autoimmune diseases boil down to a few targets plus successful clinical and commercial strategies. What are the next targets and mechanisms that could allow drug developers to recapitulate their success in new indications and refractory patient populations? Will the early academic data on durable remissions with CD19 CAR T cells have applications in diseases with less B cell involvement? And can bispecifics offer a path to reset the immune system? This Round will probe these developments and ask whether ambition in the field has changed from managing autoimmune diseases to curing them.

Chair: Paul-Peter Tak, M.D., Ph.D., CEO, Candel Therapeutics

Panelists: Gwendolyn Binder, Ph.D., President, Science & Technology, Cabaletta Bio
Aaron Esser-Kahn, Ph.D., Professor of Molecular Engineering, University of
Chicago

Samantha Singer, President & CEO, Abata Therapeutics

2:10 pm – 2:50 pm

Closing Rapporteur Plenary: What's Next For Translational Research?

Where does translational research go from here? This closing rapporteur session identifies the key takeaway messages from BioCentury's inaugural Grand Rounds Conference.

2:50 pm – 4:30 pm

Closing Networking Reception

4:30 pm – 6:00 pm

Local Ecosystem Tour

**Limited Capacity, additional registration required.
Email: conferences@biocentury.com for more information.*



Attending Organizations

**Select list of attending organizations*

BioCentury events gather decision-makers from across the biopharma ecosystem to network, partner, and debate critical issues facing the industry. Grand Rounds continues this tradition in the R&D space, at the interface of academia and industry.

5AM Ventures	F2 Ventures	Novartis
64x Bio	flanders.bio	Nvelop Therapeutics
Abata Therapeutics	FogPharma	Perceptive Advisors
Actio Biosciences	Genentech	Pi Health
Aitia	Greater Nashville Venture Capital Association (GNVCA)	ProFound Therapeutics
Alto Neuroscience	GV	Radar Therapeutics
Amazon	Hetero USA	Recursion
Anocca	Highlander Health	Regeneron
Antion Biosciences	iaso Ventures	RHEADC
Arch Venture Partners	Janux Therapeutics	Sana Biotechnology
Ascensus Therapeutics	Johns Hopkins University	Safenia Therapeutics
Astellas Institute for Regenerative Medicine	Keck School of Medicine of USC	Siren Biotechnology
Basking Biosciences	Kelonia Therapeutics	Sofinnova Partners
Biocom California	Lazard Freres	SonoThera
Biogen	Life Edit Therapeutics	SV Health Investors
BioInnovation Institute	LifeMine Therapeutics	Syncona
Boston Pharmaceuticals	Life Science Tennessee	TFC Therapeutics
Candel Therapeutics	Lightspeed	Third Rock Ventures
Cellarity	Lynch Regenerative Medicine	University of Rochester
Cellino	Mahzi Therapeutics	Vanderbilt University Medical Center
Dana Farber Cancer Institute	McKinsey & Company	VIB
DCVC Bio	MeiraGTx	Vivodyne
Deep Track Capital	Milner Therapeutics Institute	VRG Therapeutics
Deerfield Management	MPM BioImpact	Xontogeny
EG427	MSD	Zilkha Neurogenetic Institute of USC
EpiCure Therapeutics	Myeloma Investment Fund	
Epiodyne	NashBio	
ESC Advisors	NINDS/NIH	

Pre-event Networking Excursion



The National Museum of African American Music

Join us for a visit to the National Museum of African American Music, including a delightful lunch. Get the networking started early while immersing yourself in one of the jewels of Nashville, the only museum dedicated to the history of Black music. Discover the stories behind the rhythms and melodies that have shaped genres from jazz and blues to hip-hop and R&B.

The museum's expertly-curated collections share the story of the American soundtrack by integrating history and interactive technology to bring the musical heroes of the past into the present.

**Limited Capacity, additional registration required.*

Email: conferences@biocentury.com for more information

ROUNDS ABOUT TOWN

Build stronger connections with academics, investors, and biopharma execs by joining BioCentury's "Rounds About Town" walking tour. Visit Nashville honky-tonks, live music venues, and other cultural sites in Music City as you network with Grand Rounds attendees.

*Depart from Four Seasons lobby, Tuesday, Sept 10 at 7:30pm. Please note, food, drinks, and other expenses must be paid for separately.



Robert's Western World
Nashville's Home of Traditional Country Music.

416B Broadway
Nashville, TN 37203

11:00am - 3:00am
0.4 miles - 8-minute walk

Tootsie's Orchid Lounge

Famous and popular honky tonks, with 3 floors and 3 stages of live music.

422 Broadway
Nashville, TN 37203

9:30am - 3:00am
0.4 miles - 9-minute walk



Skull's Rainbow Room

Circa 1948, speakeasy-style lounge offering elevated American fare, craft drinks, and nightly burlesque.

222 Printers Alley
Nashville, TN 37219

5:00pm - 2:00am
0.5 miles - 13-minute walk

Bourbon Street Blues and Boogie Bar

Live music with Cajun cuisine & blues in Mardi Gras-themed surroundings.

220 Printers Alley
Nashville, TN 37201

11:30am - 12:00am
0.5 miles - 13-minute walk



In case you are arriving into Nashville early or staying in town after Grand Rounds 2024, here are others you may want to check out on your own



3rd & Lindsley Bar & Grill

Live music with performances from an eclectic roster of acts, plus food & drink.

818 3rd Ave S
Nashville, TN 37210

6:00pm - 12:00am
0.7 miles - 16-minute walk

**It is recommended that you take an Uber/Taxi to/from*



Rudy's Jazz Room

Intimate, unique, cozy atmosphere with live jazz nightly.

809 Gleaves St
Nashville, TN 37203

5:30 pm - 11:30 pm
Closed on Tuesdays, BUT a must-visit if you stay before or after Grand Rounds!
0.9 miles - 21-minute walk



Station Inn

World's best bluegrass, classic country, Americana and roots music.

402 12th Avenue South
Nashville, TN 37023

7:00am - 1:00am
1 mile - 23-minute walk

**It is recommended that you take an Uber/Taxi to/from*

***Cash-only establishment with a cover charge*



For questions or additional information, please contact:

BRIAN DENKER
Director, Industry Events & Operations
conferences@biocentury.com

Bonus Content

Exclusive McKinsey & Company Conference Report

At Grand Rounds, McKinsey & Company continues its 10-year role as Insights Partner at BioCentury events, presenting a conference report on key challenges in the translation of scientific advances into drug development and medical practice.



McKinsey & Company keynote presentation at the 2nd East-West Biopharma Summit, Boston, MA October 2, 2023

Join BioCentury on the Road



11th China Healthcare Summit
Oct. 30 – Nov. 1, 2024
Shanghai




**Biotech's Next Challenge:
Delivering on the Story**
Nov. 19, 2024
London



25th BioEquity Europe
May 12-14, 2025
Bruges

BioCentury's two podcasts are now available to stream on your favorite podcast platform.



Visit www.BioCentury.com for more information.

The BioCentury Show



BioCentury This Week



Partnering opens August 19, 2024

BIOCENTURY BCIQ

Your best *decisions*
start with the right *data*



Let us help you and your
team members prepare
for your 1x1 meetings.



COMPREHENSIVE/
COMPETITIVE
PIPELINES



COMPANY
PROFILES



FINANCING
ROUNDS



DEAL COMPS

Receive **complimentary access to BioCentury's business intelligence platform**. Research **pipelines, financings, deals, and exclusive analysis** to help you prepare for meetings with potential investors and partners.

BCIQ combines four databases into **one integrated intelligence solution**.

All of the content is **linked directly to BioCentury's analysis**, making it easier for your team to place the data into the right context.

Want to learn more? Schedule an online session to use BCIQ to prepare for industry conferences.



Build competitive
landscapes fast



Evaluate key financial
metrics of deals



Analyze detailed
company profiles



Discover emerging
companies



Receive custom alerts
and notifications



Save time with fully
integrated data sets

[BCIQ.BIOCENTURY.COM](https://bcIQ.BIOCENTURY.COM)

Event Organizer

BIOCENTURY For three decades BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

The BioCentury Business Intelligence Platform

ANALYSIS - BioCentury's intelligence platform supports all stages of drug development with essential analysis for: R&D, Partnering, Financing & Investment and Regulatory & Market Access.

DATA - BioCentury's BCIQ database combines 30 years of biopharma industry analysis with curated data, aiding financing, investing, and dealmaking activities.

CONFERENCES - BioCentury's C-level events are where decision-makers gather to network, partner, and debate critical issues facing the biopharma industry.

PODCASTS & WEBCASTS - BioCentury podcasts and webcasts are perfect for the busy biopharma executive on-the-go:

- BioCentury This Week podcast: Dig into the latest biopharma trends and hot topics on this weekly podcast with BioCentury analysts. Available on Apple, Spotify, YouTube.
- The BioCentury Show podcast/webcast: Industry KOLs join BioCentury's twice-monthly podcast/webcast to discuss turning science into medicine – from R&D to financing to public policy. Available on Apple, Spotify, YouTube.

Insights Partner

McKinsey & Company

McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth.

We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next. www.mckinsey.com

Founding Investors

5AM VENTURES 5AM Ventures is a leading investment firm focused on funding and building next-generation life sciences companies. 5amventures.com

ARCH VENTURE PARTNERS ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease. www.archventure.com

DEERFIELD Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care. As of December 2023, the firm manages more than \$14.6 billion in assets.

Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company. www.deerfield.com

F2 Ventures

F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact. www.f2-ventures.com



Iaso Ventures is a venture capital firm located in Boston. Our investor-operator team and strategic partner network is passionate about helping early-stage ventures succeed and move the needle in the brain health sector. iasoventures.com



Serving bold builders of the future.

For over twenty years Lightspeed has been the first investor and an early backer of some of the most innovative companies in the world. In service of bold founders with big ideas, we stand behind our companies with high conviction from Seed to Series F and beyond. lsvp.com



MPM BioImpact MPM BioImpact is a world-leading biotechnology investment firm with more than three decades of experience creating and investing in innovative biotechnology companies seeking to deliver transformative therapies to patients in the areas of highest unmet medical need. MPM BioImpact strives to power novel medical breakthroughs that transform patients' lives. It invests across the biotech landscape with its early-stage venture capital funds, a public equities fund, and impact funds investing in both private and public companies. mpmbioimpact.com

Sofinnova partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. www.sofinnovapartners.com



SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. svhealthinvestors.com



Syncona's purpose is to invest to extend and enhance human life. It does this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need, for the benefit of all our stakeholders. Syncona focuses on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Syncona's balance sheet underpins its strategy, enabling it to take a long-term view as the company looks to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders. www.synconaltd.com



We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients' lives. www.thirdrockventures.com



xontogeny Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders, and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease. We offer our experienced team and deep network of industry consultants and service providers along with seed investment capital across a variety of technologies, including therapeutics, diagnostics, and devices with the singular goal of shepherding each program through a compelling clinical proof-of-concept study. xontogeny.com

Sponsors



In our world of rapid change, the need for reliable information to make confident decisions has never been greater.

At Ipsos we believe our clients need more than a data supplier, they need a partner who can produce accurate and relevant information and turn it into actionable truth.

This is why our passionately curious experts not only provide the most precise measurement, but shape it to provide True Understanding of Society, Markets and People.

To do this we use the best of science, technology and know-how and apply the principles of security, simplicity, speed and substance to everything we do.

So that our clients can act faster, smarter and bolder.

Ultimately, success comes down to a simple truth: YOU ACT BETTER WHEN YOU ARE SURE www.ipsos.com/en-us



Leerink Partners is a highly specialized healthcare investment bank with a legacy of excellence in the financial industry. The firm's experienced team delivers innovative advisory solutions, capital raising expertise, and unique insights to empower clients to achieve their strategic objectives. Since inception the firm has advised on \$60 billion, helped clients raise over \$165 billion and has established itself as a trusted partner to healthcare companies and their investors. The firm is a broker-dealer registered with the United States Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority. www.leerink.com



Nutter Nutter, McClennan & Fish advises biotechnology companies and investors. We provide timely, pragmatic guidance to strategic buyers looking to capitalize on market opportunities, investors seeking to expand their presence, and companies looking for experienced counsel to guide them through the complexities of a transaction. We have a proven track record of successfully protecting intellectual property assets. We help clients unlock the value of their IP, creating revenue streams from licensing and sales. We also develop IP strategies which determine what innovations should be protected or bolstered and the ones to be licensed or abandoned for optimal return on investment.
www.nutter.com

Supporting Organizations



Biocom California Biocom California is the advocate for California's life science sector. We work on behalf of 1,700+ members to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs and create value-driven purchasing programs.

Founded in 1995 in San Diego, we provide the strongest public voice to research institutions and companies that fuel the local and state-wide economy and help our members produce novel solutions that improve the human condition. In addition to our headquarters, we operate core offices in LA and the Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. www.biocom.org



BII BioInnovation Institute BII offers entrepreneurially-minded researchers or anyone with a research-based idea help to bring interdisciplinary ideas to life and research to market. We offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts. Our main focus is health tech, bio-industrials and therapeutics. We envision that strong collaborations, a passion for science, and an open mind will foster research-based innovation and viable start-ups. BII does not work for profit but for the benefit of human welfare and society around the globe. bii.dk



flanders.bio flanders.bio is a dynamic, independent and member driven life sciences cluster organization with currently more than 350 members and partners from Flanders, Belgium and abroad. We enable our members and partners to create value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. Since 2004, flanders.bio and its members are the proud advocates of a reputable global-impact ecosystem in biotech and life sciences.
flanders.bio/en



gnvca The Greater Nashville Venture Capital Association (GNVCA) is a membership organization comprised of investors from pre-seed to growth equity (venture capital, angel investors, private offices, and corporate venture partners) in the greater Nashville region, working to make Middle Tennessee a premier area to launch, grow, and invest in companies.

The purpose of the GNVCA is to increase the availability of capital and talent that is available to venture capital and angel investors in the region, so that our most innovative entrepreneurs can build successful companies that create jobs and economic growth for the region. gnvca.org



LIFE SCIENCE TENNESSEE Life Science Tennessee is a statewide, nonprofit member organization whose mission is to advance and grow the life science industry in Tennessee. Life Science TN, in partnership with its foundation arm BioTN, facilitates connections between private companies, research institutions, and economic development groups, advocates for policies that support the industry at the local, state, and federal level, and manages programs that support innovation, early-stage growth, and workforce development. Life Science TN is driven by its members that are involved in the discovery and application of life science products, including world-renowned brands and research institutions as well as startup ventures.
www.lifesciencetn.org



MILNER THERAPEUTICS INSTITUTE The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme, which aims to transform pioneering science into therapies. It was founded in 2015 as a new paradigm for an academic Institution, based on bridging the gap between academia and Industry. The research institute opened in summer 2019 in the new Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, providing a physical hub for these cross-sector collaborations. We have also built a global research community of 80 affiliated organisations.

The Institute was co-founded by Tony Kouzarides and Jonathan Milner. The therapeutics concept and mission was developed following the establishment of the Milner Therapeutics Consortium by Tony Kouzarides. Jonathan Milner is a benefactor to the building of the Research Institute, which bears his name. Tony and Jonathan are also co-founders of Abcam plc, an antibody reagents provider based in Cambridge. www.milner.cam.ac.uk





Women In Bio is an organization of professionals committed to promoting careers, leadership, and entrepreneurship for all women in the life sciences.

We are an organization of professional women from all career walks in the field of life sciences. We are all volunteers and we all share the goal of enabling and empowering women to reach the highest levels of leadership, and — more importantly — to fulfill their own career aspirations.

Our members reflect the increasing spread of the life sciences. We belong to biotech and pharma companies, universities and institutes, law and accounting firms, marketing and PR firms, CROs, and CMOs. Many of our members are entrepreneurs, and a focus on entrepreneurship has remained core to WIB's mission. www.womeninbio.org

Register Online

www.BioCenturyGrandRounds.com

Registration Type	Early Bird Ends June 3, 2024	Advanced Ends August 2, 2024	Standard
Industry Pass (Non-Academic / Non-Service Provider)	\$1495	\$1695	\$1895
Academic Pass (Full-time affiliation with an educational or research institution)	\$995	\$1195	\$1395
Academic Pass + Poster Presentation* (Full-time affiliation with an educational or academic institution + poster presentation)	\$1095	\$1295	\$1495
Presenting Company Presentation Package* (Includes two passes)	\$2495	\$2795	\$3095
Presenting Company Presentation Package + Poster Presentation* (Includes two passes)	\$2695	\$2995	\$3295
Service Provider Pass (CRO, CMO, Economic Development Organizations, Law Firms, Communications/IR Firms, Consultants, Executive Recruiters, Merchants, and other service providers.)	\$1870	\$2120	\$2370

*Email: grandroundshelp@biocentury.com for additional information on how to register.

Group discounts:

Discounts are available for groups of four (4) or more from any one company. For additional information and pricing, please email: grandroundshelp@biocentury.com.



Grand Rounds 2024 will take place at:

Four Seasons Hotel Nashville

100 Demonbreun St

Nashville, TN 37201

Telephone: +1 (615) 610-6995

For details on hotel and travel arrangements, please refer to our [hotel and travel page](#) to book accommodations under the conference room block.